Dr Boreham’s Crucible: This rare blood disease tackler aims to hit investors with its best shot
While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...
ETF Daily News7d
Contrasting Pharmaxis (OTCMKTS:PXSLY) & iBio (NYSE:IBIO)
The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting ...
Stockhead on MSN1d
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agent
Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.
VIVUS Launches QSYMIA® in the United Arab Emirates
VIVUS, in collaboration with PharmaAccess, its marketing partner in the Middle East North African (MENA) region, intends to provide healthcare providers with more treatment options to combat this ...
VIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight Management
VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For LifeCAMPBELL, Calif., March 04, 2025 ...
Medscape4d
The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache
Sumatriptan and others are contraindicated in patients taking monoamine oxidase (MAO ... headaches), isometheptene (a sympathomimetic amine with vasoconstriction properties) and dichloralphenazone ...